nodes	percent_of_prediction	percent_of_DWPC	metapath
Ponatinib—ABCB11—Cyclosporine—focal segmental glomerulosclerosis	0.247	0.412	CbGbCtD
Ponatinib—ABCG2—Cyclosporine—focal segmental glomerulosclerosis	0.118	0.196	CbGbCtD
Ponatinib—CYP3A5—Cyclosporine—focal segmental glomerulosclerosis	0.0652	0.108	CbGbCtD
Ponatinib—CYP2C8—Cyclosporine—focal segmental glomerulosclerosis	0.0627	0.104	CbGbCtD
Ponatinib—ABCB1—Cyclosporine—focal segmental glomerulosclerosis	0.0424	0.0706	CbGbCtD
Ponatinib—CYP2D6—Cyclosporine—focal segmental glomerulosclerosis	0.04	0.0665	CbGbCtD
Ponatinib—CYP3A4—Cyclosporine—focal segmental glomerulosclerosis	0.0254	0.0423	CbGbCtD
Ponatinib—FGFR4—nephron tubule—focal segmental glomerulosclerosis	0.00757	0.07	CbGeAlD
Ponatinib—TEK—endothelium—focal segmental glomerulosclerosis	0.00708	0.0654	CbGeAlD
Ponatinib—FGFR4—kidney—focal segmental glomerulosclerosis	0.00665	0.0615	CbGeAlD
Ponatinib—FGFR4—cortex of kidney—focal segmental glomerulosclerosis	0.00648	0.0599	CbGeAlD
Ponatinib—SRC—endothelium—focal segmental glomerulosclerosis	0.00629	0.0581	CbGeAlD
Ponatinib—KDR—endothelium—focal segmental glomerulosclerosis	0.00578	0.0535	CbGeAlD
Ponatinib—KIT—endothelium—focal segmental glomerulosclerosis	0.00512	0.0474	CbGeAlD
Ponatinib—FGFR3—kidney—focal segmental glomerulosclerosis	0.00454	0.042	CbGeAlD
Ponatinib—BCR—nephron tubule—focal segmental glomerulosclerosis	0.00447	0.0413	CbGeAlD
Ponatinib—FGFR3—cortex of kidney—focal segmental glomerulosclerosis	0.00442	0.0409	CbGeAlD
Ponatinib—Peripheral ischaemia—Cyclosporine—focal segmental glomerulosclerosis	0.00405	0.0491	CcSEcCtD
Ponatinib—BCR—cortex of kidney—focal segmental glomerulosclerosis	0.00382	0.0354	CbGeAlD
Ponatinib—FGFR1—cortex of kidney—focal segmental glomerulosclerosis	0.0034	0.0315	CbGeAlD
Ponatinib—RET—kidney—focal segmental glomerulosclerosis	0.00313	0.0289	CbGeAlD
Ponatinib—FGFR2—kidney—focal segmental glomerulosclerosis	0.00297	0.0275	CbGeAlD
Ponatinib—TEK—kidney—focal segmental glomerulosclerosis	0.00285	0.0263	CbGeAlD
Ponatinib—TEK—cortex of kidney—focal segmental glomerulosclerosis	0.00277	0.0256	CbGeAlD
Ponatinib—Night sweats—Cyclosporine—focal segmental glomerulosclerosis	0.00274	0.0332	CcSEcCtD
Ponatinib—KDR—nephron tubule—focal segmental glomerulosclerosis	0.00265	0.0245	CbGeAlD
Ponatinib—Hypertriglyceridaemia—Cyclosporine—focal segmental glomerulosclerosis	0.00257	0.0312	CcSEcCtD
Ponatinib—SRC—kidney—focal segmental glomerulosclerosis	0.00253	0.0234	CbGeAlD
Ponatinib—Folliculitis—Cyclosporine—focal segmental glomerulosclerosis	0.00235	0.0285	CcSEcCtD
Ponatinib—KIT—nephron tubule—focal segmental glomerulosclerosis	0.00235	0.0217	CbGeAlD
Ponatinib—KDR—kidney—focal segmental glomerulosclerosis	0.00233	0.0215	CbGeAlD
Ponatinib—KDR—cortex of kidney—focal segmental glomerulosclerosis	0.00227	0.021	CbGeAlD
Ponatinib—Blood triglycerides increased—Cyclosporine—focal segmental glomerulosclerosis	0.00225	0.0274	CcSEcCtD
Ponatinib—KIT—kidney—focal segmental glomerulosclerosis	0.00206	0.0191	CbGeAlD
Ponatinib—ABL1—nephron tubule—focal segmental glomerulosclerosis	0.00204	0.0189	CbGeAlD
Ponatinib—KIT—cortex of kidney—focal segmental glomerulosclerosis	0.00201	0.0186	CbGeAlD
Ponatinib—Hepatotoxicity—Cyclosporine—focal segmental glomerulosclerosis	0.00191	0.0232	CcSEcCtD
Ponatinib—Hyperaesthesia—Cyclosporine—focal segmental glomerulosclerosis	0.00188	0.0228	CcSEcCtD
Ponatinib—ABL1—kidney—focal segmental glomerulosclerosis	0.0018	0.0166	CbGeAlD
Ponatinib—ABL1—cortex of kidney—focal segmental glomerulosclerosis	0.00175	0.0162	CbGeAlD
Ponatinib—Neoplasm malignant—Cyclosporine—focal segmental glomerulosclerosis	0.00173	0.021	CcSEcCtD
Ponatinib—Cardiovascular disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00168	0.0204	CcSEcCtD
Ponatinib—Cellulitis—Cyclosporine—focal segmental glomerulosclerosis	0.00162	0.0197	CcSEcCtD
Ponatinib—Hyperuricaemia—Cyclosporine—focal segmental glomerulosclerosis	0.00159	0.0193	CcSEcCtD
Ponatinib—Creatinine increased—Cyclosporine—focal segmental glomerulosclerosis	0.00155	0.0188	CcSEcCtD
Ponatinib—Blood uric acid increased—Cyclosporine—focal segmental glomerulosclerosis	0.0015	0.0183	CcSEcCtD
Ponatinib—Influenza like illness—Cyclosporine—focal segmental glomerulosclerosis	0.00143	0.0174	CcSEcCtD
Ponatinib—Fluid retention—Cyclosporine—focal segmental glomerulosclerosis	0.0014	0.017	CcSEcCtD
Ponatinib—Neuropathy—Cyclosporine—focal segmental glomerulosclerosis	0.00139	0.0168	CcSEcCtD
Ponatinib—ABCG2—nephron tubule—focal segmental glomerulosclerosis	0.00129	0.0119	CbGeAlD
Ponatinib—Sepsis—Cyclosporine—focal segmental glomerulosclerosis	0.00128	0.0156	CcSEcCtD
Ponatinib—CYP3A5—nephron tubule—focal segmental glomerulosclerosis	0.0012	0.0111	CbGeAlD
Ponatinib—CYP2C8—kidney—focal segmental glomerulosclerosis	0.00116	0.0108	CbGeAlD
Ponatinib—Hot flush—Cyclosporine—focal segmental glomerulosclerosis	0.00115	0.0139	CcSEcCtD
Ponatinib—Menopausal symptoms—Cyclosporine—focal segmental glomerulosclerosis	0.00114	0.0138	CcSEcCtD
Ponatinib—Cardiac failure—Cyclosporine—focal segmental glomerulosclerosis	0.0011	0.0133	CcSEcCtD
Ponatinib—Lethargy—Cyclosporine—focal segmental glomerulosclerosis	0.00109	0.0133	CcSEcCtD
Ponatinib—Migraine—Cyclosporine—focal segmental glomerulosclerosis	0.00106	0.0128	CcSEcCtD
Ponatinib—CYP3A5—kidney—focal segmental glomerulosclerosis	0.00105	0.00972	CbGeAlD
Ponatinib—CYP3A5—cortex of kidney—focal segmental glomerulosclerosis	0.00102	0.00947	CbGeAlD
Ponatinib—Blood creatinine increased—Cyclosporine—focal segmental glomerulosclerosis	0.001	0.0122	CcSEcCtD
Ponatinib—Dry skin—Cyclosporine—focal segmental glomerulosclerosis	0.000983	0.0119	CcSEcCtD
Ponatinib—Breast disorder—Cyclosporine—focal segmental glomerulosclerosis	0.000969	0.0118	CcSEcCtD
Ponatinib—Abdominal distension—Cyclosporine—focal segmental glomerulosclerosis	0.000933	0.0113	CcSEcCtD
Ponatinib—Pancreatitis—Cyclosporine—focal segmental glomerulosclerosis	0.000909	0.011	CcSEcCtD
Ponatinib—Abdominal discomfort—Cyclosporine—focal segmental glomerulosclerosis	0.000888	0.0108	CcSEcCtD
Ponatinib—Upper respiratory tract infection—Cyclosporine—focal segmental glomerulosclerosis	0.000861	0.0105	CcSEcCtD
Ponatinib—Weight decreased—Cyclosporine—focal segmental glomerulosclerosis	0.000838	0.0102	CcSEcCtD
Ponatinib—Hyperglycaemia—Cyclosporine—focal segmental glomerulosclerosis	0.000836	0.0101	CcSEcCtD
Ponatinib—Pneumonia—Cyclosporine—focal segmental glomerulosclerosis	0.000831	0.0101	CcSEcCtD
Ponatinib—Infestation NOS—Cyclosporine—focal segmental glomerulosclerosis	0.000826	0.01	CcSEcCtD
Ponatinib—Infestation—Cyclosporine—focal segmental glomerulosclerosis	0.000826	0.01	CcSEcCtD
Ponatinib—Acute coronary syndrome—Cyclosporine—focal segmental glomerulosclerosis	0.000815	0.00989	CcSEcCtD
Ponatinib—Neuropathy peripheral—Cyclosporine—focal segmental glomerulosclerosis	0.00081	0.00983	CcSEcCtD
Ponatinib—Myocardial infarction—Cyclosporine—focal segmental glomerulosclerosis	0.00081	0.00983	CcSEcCtD
Ponatinib—Jaundice—Cyclosporine—focal segmental glomerulosclerosis	0.000805	0.00978	CcSEcCtD
Ponatinib—Stomatitis—Cyclosporine—focal segmental glomerulosclerosis	0.000805	0.00978	CcSEcCtD
Ponatinib—Urinary tract infection—Cyclosporine—focal segmental glomerulosclerosis	0.000803	0.00975	CcSEcCtD
Ponatinib—CYP3A4—kidney—focal segmental glomerulosclerosis	0.000789	0.00729	CbGeAlD
Ponatinib—Hepatobiliary disease—Cyclosporine—focal segmental glomerulosclerosis	0.000781	0.00949	CcSEcCtD
Ponatinib—Epistaxis—Cyclosporine—focal segmental glomerulosclerosis	0.000779	0.00946	CcSEcCtD
Ponatinib—CYP2D6—kidney—focal segmental glomerulosclerosis	0.000776	0.00718	CbGeAlD
Ponatinib—Haemoglobin—Cyclosporine—focal segmental glomerulosclerosis	0.000746	0.00905	CcSEcCtD
Ponatinib—Haemorrhage—Cyclosporine—focal segmental glomerulosclerosis	0.000742	0.009	CcSEcCtD
Ponatinib—Hypoaesthesia—Cyclosporine—focal segmental glomerulosclerosis	0.000738	0.00896	CcSEcCtD
Ponatinib—Connective tissue disorder—Cyclosporine—focal segmental glomerulosclerosis	0.000729	0.00885	CcSEcCtD
Ponatinib—Visual impairment—Cyclosporine—focal segmental glomerulosclerosis	0.000715	0.00868	CcSEcCtD
Ponatinib—Flushing—Cyclosporine—focal segmental glomerulosclerosis	0.000688	0.00836	CcSEcCtD
Ponatinib—Angiopathy—Cyclosporine—focal segmental glomerulosclerosis	0.000673	0.00817	CcSEcCtD
Ponatinib—Mediastinal disorder—Cyclosporine—focal segmental glomerulosclerosis	0.000669	0.00812	CcSEcCtD
Ponatinib—Chills—Cyclosporine—focal segmental glomerulosclerosis	0.000666	0.00808	CcSEcCtD
Ponatinib—Arrhythmia—Cyclosporine—focal segmental glomerulosclerosis	0.000663	0.00804	CcSEcCtD
Ponatinib—Alopecia—Cyclosporine—focal segmental glomerulosclerosis	0.000655	0.00796	CcSEcCtD
Ponatinib—Mental disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00065	0.00789	CcSEcCtD
Ponatinib—Malnutrition—Cyclosporine—focal segmental glomerulosclerosis	0.000646	0.00784	CcSEcCtD
Ponatinib—ABCB1—nephron tubule—focal segmental glomerulosclerosis	0.000635	0.00587	CbGeAlD
Ponatinib—Muscle spasms—Cyclosporine—focal segmental glomerulosclerosis	0.000621	0.00754	CcSEcCtD
Ponatinib—Vision blurred—Cyclosporine—focal segmental glomerulosclerosis	0.000609	0.00739	CcSEcCtD
Ponatinib—Anaemia—Cyclosporine—focal segmental glomerulosclerosis	0.000597	0.00724	CcSEcCtD
Ponatinib—Leukopenia—Cyclosporine—focal segmental glomerulosclerosis	0.000578	0.00702	CcSEcCtD
Ponatinib—Cough—Cyclosporine—focal segmental glomerulosclerosis	0.000563	0.00684	CcSEcCtD
Ponatinib—ABCB1—kidney—focal segmental glomerulosclerosis	0.000558	0.00516	CbGeAlD
Ponatinib—Hypertension—Cyclosporine—focal segmental glomerulosclerosis	0.000557	0.00677	CcSEcCtD
Ponatinib—Myalgia—Cyclosporine—focal segmental glomerulosclerosis	0.00055	0.00667	CcSEcCtD
Ponatinib—Arthralgia—Cyclosporine—focal segmental glomerulosclerosis	0.00055	0.00667	CcSEcCtD
Ponatinib—Unspecified disorder of skin and subcutaneous tissue—Cyclosporine—focal segmental glomerulosclerosis	0.000546	0.00663	CcSEcCtD
Ponatinib—ABCB1—cortex of kidney—focal segmental glomerulosclerosis	0.000544	0.00503	CbGeAlD
Ponatinib—Dry mouth—Cyclosporine—focal segmental glomerulosclerosis	0.000538	0.00653	CcSEcCtD
Ponatinib—Oedema—Cyclosporine—focal segmental glomerulosclerosis	0.000527	0.0064	CcSEcCtD
Ponatinib—Infection—Cyclosporine—focal segmental glomerulosclerosis	0.000524	0.00636	CcSEcCtD
Ponatinib—Nervous system disorder—Cyclosporine—focal segmental glomerulosclerosis	0.000517	0.00627	CcSEcCtD
Ponatinib—Thrombocytopenia—Cyclosporine—focal segmental glomerulosclerosis	0.000516	0.00626	CcSEcCtD
Ponatinib—Skin disorder—Cyclosporine—focal segmental glomerulosclerosis	0.000512	0.00621	CcSEcCtD
Ponatinib—Hyperhidrosis—Cyclosporine—focal segmental glomerulosclerosis	0.000509	0.00618	CcSEcCtD
Ponatinib—Musculoskeletal discomfort—Cyclosporine—focal segmental glomerulosclerosis	0.00048	0.00583	CcSEcCtD
Ponatinib—Insomnia—Cyclosporine—focal segmental glomerulosclerosis	0.000477	0.00579	CcSEcCtD
Ponatinib—Paraesthesia—Cyclosporine—focal segmental glomerulosclerosis	0.000473	0.00574	CcSEcCtD
Ponatinib—Dyspnoea—Cyclosporine—focal segmental glomerulosclerosis	0.00047	0.0057	CcSEcCtD
Ponatinib—Dyspepsia—Cyclosporine—focal segmental glomerulosclerosis	0.000464	0.00563	CcSEcCtD
Ponatinib—Decreased appetite—Cyclosporine—focal segmental glomerulosclerosis	0.000458	0.00556	CcSEcCtD
Ponatinib—Gastrointestinal disorder—Cyclosporine—focal segmental glomerulosclerosis	0.000455	0.00552	CcSEcCtD
Ponatinib—Fatigue—Cyclosporine—focal segmental glomerulosclerosis	0.000454	0.00552	CcSEcCtD
Ponatinib—Constipation—Cyclosporine—focal segmental glomerulosclerosis	0.000451	0.00547	CcSEcCtD
Ponatinib—Pain—Cyclosporine—focal segmental glomerulosclerosis	0.000451	0.00547	CcSEcCtD
Ponatinib—Gastrointestinal pain—Cyclosporine—focal segmental glomerulosclerosis	0.000431	0.00523	CcSEcCtD
Ponatinib—Abdominal pain—Cyclosporine—focal segmental glomerulosclerosis	0.000417	0.00506	CcSEcCtD
Ponatinib—Body temperature increased—Cyclosporine—focal segmental glomerulosclerosis	0.000417	0.00506	CcSEcCtD
Ponatinib—Asthenia—Cyclosporine—focal segmental glomerulosclerosis	0.000378	0.00459	CcSEcCtD
Ponatinib—Pruritus—Cyclosporine—focal segmental glomerulosclerosis	0.000373	0.00453	CcSEcCtD
Ponatinib—Diarrhoea—Cyclosporine—focal segmental glomerulosclerosis	0.000361	0.00438	CcSEcCtD
Ponatinib—Dizziness—Cyclosporine—focal segmental glomerulosclerosis	0.000348	0.00423	CcSEcCtD
Ponatinib—Vomiting—Cyclosporine—focal segmental glomerulosclerosis	0.000335	0.00407	CcSEcCtD
Ponatinib—Rash—Cyclosporine—focal segmental glomerulosclerosis	0.000332	0.00403	CcSEcCtD
Ponatinib—Dermatitis—Cyclosporine—focal segmental glomerulosclerosis	0.000332	0.00403	CcSEcCtD
Ponatinib—Headache—Cyclosporine—focal segmental glomerulosclerosis	0.00033	0.00401	CcSEcCtD
Ponatinib—Nausea—Cyclosporine—focal segmental glomerulosclerosis	0.000313	0.0038	CcSEcCtD
Ponatinib—Imatinib—ALB—focal segmental glomerulosclerosis	0.000153	1	CrCbGaD
Ponatinib—FGFR4—Disease—SERPINE1—focal segmental glomerulosclerosis	4.73e-05	0.000227	CbGpPWpGaD
Ponatinib—BCR—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	4.71e-05	0.000226	CbGpPWpGaD
Ponatinib—FGFR1—Immune System—CD79A—focal segmental glomerulosclerosis	4.62e-05	0.000222	CbGpPWpGaD
Ponatinib—PDGFRA—Immune System—CD79A—focal segmental glomerulosclerosis	4.61e-05	0.000221	CbGpPWpGaD
Ponatinib—SRC—Developmental Biology—LPL—focal segmental glomerulosclerosis	4.59e-05	0.00022	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism of lipids and lipoproteins—LIPC—focal segmental glomerulosclerosis	4.56e-05	0.000219	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—COL4A3—focal segmental glomerulosclerosis	4.55e-05	0.000218	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—AGTR1—focal segmental glomerulosclerosis	4.53e-05	0.000217	CbGpPWpGaD
Ponatinib—LCK—Adaptive Immune System—CD40LG—focal segmental glomerulosclerosis	4.48e-05	0.000215	CbGpPWpGaD
Ponatinib—LYN—Axon guidance—MMP9—focal segmental glomerulosclerosis	4.46e-05	0.000214	CbGpPWpGaD
Ponatinib—ABCB11—Metabolism of lipids and lipoproteins—ALB—focal segmental glomerulosclerosis	4.45e-05	0.000214	CbGpPWpGaD
Ponatinib—ABL1—Axon guidance—MMP9—focal segmental glomerulosclerosis	4.44e-05	0.000213	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—COL4A1—focal segmental glomerulosclerosis	4.41e-05	0.000211	CbGpPWpGaD
Ponatinib—ABCB11—Metabolism—CTGF—focal segmental glomerulosclerosis	4.36e-05	0.000209	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—GNAQ—focal segmental glomerulosclerosis	4.32e-05	0.000207	CbGpPWpGaD
Ponatinib—FGFR4—Signaling Pathways—AGT—focal segmental glomerulosclerosis	4.31e-05	0.000207	CbGpPWpGaD
Ponatinib—SRC—Axon guidance—MMP2—focal segmental glomerulosclerosis	4.31e-05	0.000207	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—COL4A4—focal segmental glomerulosclerosis	4.25e-05	0.000204	CbGpPWpGaD
Ponatinib—BCR—Disease—TGFB1—focal segmental glomerulosclerosis	4.24e-05	0.000203	CbGpPWpGaD
Ponatinib—LYN—Developmental Biology—MMP2—focal segmental glomerulosclerosis	4.24e-05	0.000203	CbGpPWpGaD
Ponatinib—ABL1—Developmental Biology—MMP2—focal segmental glomerulosclerosis	4.22e-05	0.000202	CbGpPWpGaD
Ponatinib—FGFR3—Disease—NOS2—focal segmental glomerulosclerosis	4.16e-05	0.000199	CbGpPWpGaD
Ponatinib—LCK—Platelet activation, signaling and aggregation—TGFB1—focal segmental glomerulosclerosis	4.1e-05	0.000196	CbGpPWpGaD
Ponatinib—LYN—Hemostasis—SERPINE1—focal segmental glomerulosclerosis	4.08e-05	0.000196	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—TRPC6—focal segmental glomerulosclerosis	4.08e-05	0.000196	CbGpPWpGaD
Ponatinib—SRC—Integrated Pancreatic Cancer Pathway—TGFB1—focal segmental glomerulosclerosis	4.07e-05	0.000195	CbGpPWpGaD
Ponatinib—LYN—Hemostasis—ALB—focal segmental glomerulosclerosis	4.07e-05	0.000195	CbGpPWpGaD
Ponatinib—LYN—Immune System—CD79A—focal segmental glomerulosclerosis	4.06e-05	0.000195	CbGpPWpGaD
Ponatinib—ABL1—Hemostasis—SERPINE1—focal segmental glomerulosclerosis	4.06e-05	0.000195	CbGpPWpGaD
Ponatinib—KDR—Developmental Biology—TGFB1—focal segmental glomerulosclerosis	4.06e-05	0.000194	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—AGTR2—focal segmental glomerulosclerosis	4.05e-05	0.000194	CbGpPWpGaD
Ponatinib—ABL1—Hemostasis—ALB—focal segmental glomerulosclerosis	4.05e-05	0.000194	CbGpPWpGaD
Ponatinib—ABL1—Immune System—CD79A—focal segmental glomerulosclerosis	4.05e-05	0.000194	CbGpPWpGaD
Ponatinib—FGFR2—Immune System—CD40LG—focal segmental glomerulosclerosis	4.04e-05	0.000194	CbGpPWpGaD
Ponatinib—LCK—Hemostasis—FN1—focal segmental glomerulosclerosis	4.02e-05	0.000193	CbGpPWpGaD
Ponatinib—ABCB11—Metabolism—GNAQ—focal segmental glomerulosclerosis	4.02e-05	0.000193	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism of lipids and lipoproteins—CTGF—focal segmental glomerulosclerosis	4.01e-05	0.000192	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—TRPC6—focal segmental glomerulosclerosis	4e-05	0.000192	CbGpPWpGaD
Ponatinib—FGFR4—Signaling Pathways—FN1—focal segmental glomerulosclerosis	3.98e-05	0.000191	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—AGTR2—focal segmental glomerulosclerosis	3.98e-05	0.000191	CbGpPWpGaD
Ponatinib—LCK—Hemostasis—NOS2—focal segmental glomerulosclerosis	3.97e-05	0.00019	CbGpPWpGaD
Ponatinib—KIT—Immune System—CD40LG—focal segmental glomerulosclerosis	3.97e-05	0.00019	CbGpPWpGaD
Ponatinib—SRC—Adaptive Immune System—CD40LG—focal segmental glomerulosclerosis	3.96e-05	0.00019	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—AGTR1—focal segmental glomerulosclerosis	3.95e-05	0.000189	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—COL4A1—focal segmental glomerulosclerosis	3.9e-05	0.000187	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—EDN1—focal segmental glomerulosclerosis	3.84e-05	0.000184	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—TRPC6—focal segmental glomerulosclerosis	3.8e-05	0.000182	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—TRPC6—focal segmental glomerulosclerosis	3.79e-05	0.000182	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—AGTR2—focal segmental glomerulosclerosis	3.78e-05	0.000181	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—AGTR2—focal segmental glomerulosclerosis	3.77e-05	0.000181	CbGpPWpGaD
Ponatinib—FGFR1—Immune System—CD40LG—focal segmental glomerulosclerosis	3.77e-05	0.000181	CbGpPWpGaD
Ponatinib—PDGFRA—Immune System—CD40LG—focal segmental glomerulosclerosis	3.76e-05	0.00018	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—LPL—focal segmental glomerulosclerosis	3.73e-05	0.000179	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—COL4A3—focal segmental glomerulosclerosis	3.73e-05	0.000179	CbGpPWpGaD
Ponatinib—ABCB1—Transmembrane transport of small molecules—TRPC6—focal segmental glomerulosclerosis	3.67e-05	0.000176	CbGpPWpGaD
Ponatinib—FGFR2—Disease—LPL—focal segmental glomerulosclerosis	3.66e-05	0.000176	CbGpPWpGaD
Ponatinib—SRC—Platelet activation, signaling and aggregation—TGFB1—focal segmental glomerulosclerosis	3.63e-05	0.000174	CbGpPWpGaD
Ponatinib—FGFR1—Developmental Biology—MMP9—focal segmental glomerulosclerosis	3.62e-05	0.000174	CbGpPWpGaD
Ponatinib—BCR—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	3.6e-05	0.000173	CbGpPWpGaD
Ponatinib—KIT—Disease—LPL—focal segmental glomerulosclerosis	3.6e-05	0.000172	CbGpPWpGaD
Ponatinib—SRC—Hemostasis—FN1—focal segmental glomerulosclerosis	3.56e-05	0.000171	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—SPP1—focal segmental glomerulosclerosis	3.53e-05	0.000169	CbGpPWpGaD
Ponatinib—SRC—Hemostasis—NOS2—focal segmental glomerulosclerosis	3.52e-05	0.000169	CbGpPWpGaD
Ponatinib—FGFR3—Disease—SERPINE1—focal segmental glomerulosclerosis	3.5e-05	0.000168	CbGpPWpGaD
Ponatinib—FGFR1—Disease—LPL—focal segmental glomerulosclerosis	3.41e-05	0.000164	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—GNAQ—focal segmental glomerulosclerosis	3.41e-05	0.000163	CbGpPWpGaD
Ponatinib—PDGFRA—Disease—LPL—focal segmental glomerulosclerosis	3.4e-05	0.000163	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—GNAQ—focal segmental glomerulosclerosis	3.35e-05	0.000161	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—EDN1—focal segmental glomerulosclerosis	3.35e-05	0.000161	CbGpPWpGaD
Ponatinib—LCK—Hemostasis—SERPINE1—focal segmental glomerulosclerosis	3.34e-05	0.00016	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—TRPC6—focal segmental glomerulosclerosis	3.34e-05	0.00016	CbGpPWpGaD
Ponatinib—LCK—Hemostasis—ALB—focal segmental glomerulosclerosis	3.34e-05	0.00016	CbGpPWpGaD
Ponatinib—LCK—Immune System—CD79A—focal segmental glomerulosclerosis	3.33e-05	0.00016	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—AGTR2—focal segmental glomerulosclerosis	3.32e-05	0.000159	CbGpPWpGaD
Ponatinib—FGFR4—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	3.32e-05	0.000159	CbGpPWpGaD
Ponatinib—LYN—Immune System—CD40LG—focal segmental glomerulosclerosis	3.31e-05	0.000159	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—COL4A3—focal segmental glomerulosclerosis	3.3e-05	0.000158	CbGpPWpGaD
Ponatinib—ABL1—Immune System—CD40LG—focal segmental glomerulosclerosis	3.3e-05	0.000158	CbGpPWpGaD
Ponatinib—ABCG2—Metabolism—LIPC—focal segmental glomerulosclerosis	3.27e-05	0.000157	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—LPL—focal segmental glomerulosclerosis	3.25e-05	0.000156	CbGpPWpGaD
Ponatinib—SRC—Axon guidance—MMP9—focal segmental glomerulosclerosis	3.24e-05	0.000155	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—AGT—focal segmental glomerulosclerosis	3.19e-05	0.000153	CbGpPWpGaD
Ponatinib—LYN—Developmental Biology—MMP9—focal segmental glomerulosclerosis	3.19e-05	0.000153	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—GNAQ—focal segmental glomerulosclerosis	3.18e-05	0.000152	CbGpPWpGaD
Ponatinib—ABL1—Developmental Biology—MMP9—focal segmental glomerulosclerosis	3.17e-05	0.000152	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—GNAQ—focal segmental glomerulosclerosis	3.17e-05	0.000152	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—AGTR1—focal segmental glomerulosclerosis	3.12e-05	0.000149	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—SPP1—focal segmental glomerulosclerosis	3.08e-05	0.000148	CbGpPWpGaD
Ponatinib—SRC—Developmental Biology—MMP2—focal segmental glomerulosclerosis	3.08e-05	0.000147	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—AGTR1—focal segmental glomerulosclerosis	3.06e-05	0.000147	CbGpPWpGaD
Ponatinib—ABCB11—Metabolism—LPL—focal segmental glomerulosclerosis	3.02e-05	0.000145	CbGpPWpGaD
Ponatinib—FGFR4—Disease—TGFB1—focal segmental glomerulosclerosis	2.99e-05	0.000143	CbGpPWpGaD
Ponatinib—FGFR1—Developmental Biology—TGFB1—focal segmental glomerulosclerosis	2.98e-05	0.000143	CbGpPWpGaD
Ponatinib—BCR—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	2.97e-05	0.000142	CbGpPWpGaD
Ponatinib—SRC—Hemostasis—SERPINE1—focal segmental glomerulosclerosis	2.96e-05	0.000142	CbGpPWpGaD
Ponatinib—SRC—Hemostasis—ALB—focal segmental glomerulosclerosis	2.95e-05	0.000142	CbGpPWpGaD
Ponatinib—SRC—Immune System—CD79A—focal segmental glomerulosclerosis	2.95e-05	0.000141	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—FN1—focal segmental glomerulosclerosis	2.95e-05	0.000141	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—AGTR1—focal segmental glomerulosclerosis	2.91e-05	0.000139	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—AGTR1—focal segmental glomerulosclerosis	2.9e-05	0.000139	CbGpPWpGaD
Ponatinib—ABCG2—Metabolism—CTGF—focal segmental glomerulosclerosis	2.88e-05	0.000138	CbGpPWpGaD
Ponatinib—FGFR2—Disease—NOS2—focal segmental glomerulosclerosis	2.86e-05	0.000137	CbGpPWpGaD
Ponatinib—KIT—Disease—NOS2—focal segmental glomerulosclerosis	2.81e-05	0.000135	CbGpPWpGaD
Ponatinib—ABCG2—Transmembrane transport of small molecules—ALB—focal segmental glomerulosclerosis	2.8e-05	0.000134	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—GNAQ—focal segmental glomerulosclerosis	2.8e-05	0.000134	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism of lipids and lipoproteins—LPL—focal segmental glomerulosclerosis	2.78e-05	0.000133	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—AGT—focal segmental glomerulosclerosis	2.78e-05	0.000133	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—TRPC6—focal segmental glomerulosclerosis	2.74e-05	0.000131	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—AGTR2—focal segmental glomerulosclerosis	2.72e-05	0.000131	CbGpPWpGaD
Ponatinib—LCK—Immune System—CD40LG—focal segmental glomerulosclerosis	2.72e-05	0.00013	CbGpPWpGaD
Ponatinib—FGFR1—Disease—NOS2—focal segmental glomerulosclerosis	2.67e-05	0.000128	CbGpPWpGaD
Ponatinib—PDGFRA—Disease—NOS2—focal segmental glomerulosclerosis	2.66e-05	0.000128	CbGpPWpGaD
Ponatinib—ABCG2—Metabolism—GNAQ—focal segmental glomerulosclerosis	2.65e-05	0.000127	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—EDN1—focal segmental glomerulosclerosis	2.64e-05	0.000127	CbGpPWpGaD
Ponatinib—LYN—Developmental Biology—TGFB1—focal segmental glomerulosclerosis	2.63e-05	0.000126	CbGpPWpGaD
Ponatinib—ABL1—Developmental Biology—TGFB1—focal segmental glomerulosclerosis	2.61e-05	0.000125	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—EDN1—focal segmental glomerulosclerosis	2.6e-05	0.000124	CbGpPWpGaD
Ponatinib—ABCB11—Metabolism—AGT—focal segmental glomerulosclerosis	2.58e-05	0.000124	CbGpPWpGaD
Ponatinib—LYN—Hemostasis—TGFB1—focal segmental glomerulosclerosis	2.58e-05	0.000123	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—FN1—focal segmental glomerulosclerosis	2.57e-05	0.000123	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—LPL—focal segmental glomerulosclerosis	2.56e-05	0.000123	CbGpPWpGaD
Ponatinib—ABL1—Hemostasis—TGFB1—focal segmental glomerulosclerosis	2.56e-05	0.000123	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—AGTR1—focal segmental glomerulosclerosis	2.56e-05	0.000123	CbGpPWpGaD
Ponatinib—FGFR4—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	2.54e-05	0.000122	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—LPL—focal segmental glomerulosclerosis	2.52e-05	0.000121	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—EDN1—focal segmental glomerulosclerosis	2.46e-05	0.000118	CbGpPWpGaD
Ponatinib—LCK—Disease—LPL—focal segmental glomerulosclerosis	2.46e-05	0.000118	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—EDN1—focal segmental glomerulosclerosis	2.46e-05	0.000118	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	2.45e-05	0.000118	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—SPP1—focal segmental glomerulosclerosis	2.43e-05	0.000116	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—TRPC6—focal segmental glomerulosclerosis	2.43e-05	0.000116	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—AGTR2—focal segmental glomerulosclerosis	2.41e-05	0.000116	CbGpPWpGaD
Ponatinib—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—focal segmental glomerulosclerosis	2.41e-05	0.000116	CbGpPWpGaD
Ponatinib—FGFR2—Disease—SERPINE1—focal segmental glomerulosclerosis	2.41e-05	0.000115	CbGpPWpGaD
Ponatinib—SRC—Immune System—CD40LG—focal segmental glomerulosclerosis	2.4e-05	0.000115	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—LPL—focal segmental glomerulosclerosis	2.39e-05	0.000115	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—SPP1—focal segmental glomerulosclerosis	2.39e-05	0.000114	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—LPL—focal segmental glomerulosclerosis	2.38e-05	0.000114	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism of lipids and lipoproteins—AGT—focal segmental glomerulosclerosis	2.38e-05	0.000114	CbGpPWpGaD
Ponatinib—KIT—Disease—SERPINE1—focal segmental glomerulosclerosis	2.37e-05	0.000113	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—LIPC—focal segmental glomerulosclerosis	2.34e-05	0.000112	CbGpPWpGaD
Ponatinib—SRC—Developmental Biology—MMP9—focal segmental glomerulosclerosis	2.31e-05	0.000111	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—GNAQ—focal segmental glomerulosclerosis	2.29e-05	0.00011	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—SPP1—focal segmental glomerulosclerosis	2.26e-05	0.000109	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—SPP1—focal segmental glomerulosclerosis	2.26e-05	0.000108	CbGpPWpGaD
Ponatinib—FGFR1—Disease—SERPINE1—focal segmental glomerulosclerosis	2.24e-05	0.000108	CbGpPWpGaD
Ponatinib—PDGFRA—Disease—SERPINE1—focal segmental glomerulosclerosis	2.24e-05	0.000107	CbGpPWpGaD
Ponatinib—FGFR3—Disease—TGFB1—focal segmental glomerulosclerosis	2.21e-05	0.000106	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—AGT—focal segmental glomerulosclerosis	2.19e-05	0.000105	CbGpPWpGaD
Ponatinib—SRC—Disease—LPL—focal segmental glomerulosclerosis	2.18e-05	0.000104	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—EDN1—focal segmental glomerulosclerosis	2.17e-05	0.000104	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—AGT—focal segmental glomerulosclerosis	2.15e-05	0.000103	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	2.14e-05	0.000102	CbGpPWpGaD
Ponatinib—LCK—Hemostasis—TGFB1—focal segmental glomerulosclerosis	2.11e-05	0.000101	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—LPL—focal segmental glomerulosclerosis	2.1e-05	0.000101	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—AGTR1—focal segmental glomerulosclerosis	2.1e-05	0.0001	CbGpPWpGaD
Ponatinib—FGFR4—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	2.09e-05	0.0001	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—CTGF—focal segmental glomerulosclerosis	2.06e-05	9.9e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—AGT—focal segmental glomerulosclerosis	2.04e-05	9.8e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—AGT—focal segmental glomerulosclerosis	2.04e-05	9.78e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—LIPC—focal segmental glomerulosclerosis	2.03e-05	9.74e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—GNAQ—focal segmental glomerulosclerosis	2.03e-05	9.73e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—FN1—focal segmental glomerulosclerosis	2.03e-05	9.72e-05	CbGpPWpGaD
Ponatinib—ABCG2—Metabolism—LPL—focal segmental glomerulosclerosis	2e-05	9.57e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—SPP1—focal segmental glomerulosclerosis	1.99e-05	9.55e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—FN1—focal segmental glomerulosclerosis	1.99e-05	9.55e-05	CbGpPWpGaD
Ponatinib—ABCB11—Metabolism—ALB—focal segmental glomerulosclerosis	1.98e-05	9.51e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—NOS2—focal segmental glomerulosclerosis	1.92e-05	9.22e-05	CbGpPWpGaD
Ponatinib—SRC—Developmental Biology—TGFB1—focal segmental glomerulosclerosis	1.91e-05	9.13e-05	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—GNAQ—focal segmental glomerulosclerosis	1.9e-05	9.12e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—FN1—focal segmental glomerulosclerosis	1.89e-05	9.06e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—FN1—focal segmental glomerulosclerosis	1.88e-05	9.04e-05	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	1.88e-05	9.01e-05	CbGpPWpGaD
Ponatinib—SRC—Hemostasis—TGFB1—focal segmental glomerulosclerosis	1.87e-05	8.96e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—AGTR1—focal segmental glomerulosclerosis	1.85e-05	8.89e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism of lipids and lipoproteins—ALB—focal segmental glomerulosclerosis	1.83e-05	8.76e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—AGT—focal segmental glomerulosclerosis	1.8e-05	8.63e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—CTGF—focal segmental glomerulosclerosis	1.79e-05	8.57e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—EDN1—focal segmental glomerulosclerosis	1.78e-05	8.52e-05	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—LIPC—focal segmental glomerulosclerosis	1.77e-05	8.48e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—LPL—focal segmental glomerulosclerosis	1.72e-05	8.26e-05	CbGpPWpGaD
Ponatinib—ABCG2—Metabolism—AGT—focal segmental glomerulosclerosis	1.71e-05	8.19e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—NOS2—focal segmental glomerulosclerosis	1.7e-05	8.16e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	1.69e-05	8.09e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—LIPC—focal segmental glomerulosclerosis	1.67e-05	7.99e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—FN1—focal segmental glomerulosclerosis	1.66e-05	7.97e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	1.66e-05	7.94e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—GNAQ—focal segmental glomerulosclerosis	1.65e-05	7.9e-05	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	1.64e-05	7.85e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—SPP1—focal segmental glomerulosclerosis	1.63e-05	7.83e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—SERPINE1—focal segmental glomerulosclerosis	1.62e-05	7.76e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—EDN1—focal segmental glomerulosclerosis	1.57e-05	7.54e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	1.57e-05	7.54e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	1.57e-05	7.52e-05	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—CTGF—focal segmental glomerulosclerosis	1.56e-05	7.47e-05	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	1.55e-05	7.42e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—LPL—focal segmental glomerulosclerosis	1.53e-05	7.32e-05	CbGpPWpGaD
Ponatinib—FGFR2—Disease—TGFB1—focal segmental glomerulosclerosis	1.52e-05	7.29e-05	CbGpPWpGaD
Ponatinib—ABCB1—Transmembrane transport of small molecules—ALB—focal segmental glomerulosclerosis	1.51e-05	7.26e-05	CbGpPWpGaD
Ponatinib—KIT—Disease—TGFB1—focal segmental glomerulosclerosis	1.49e-05	7.16e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—AGT—focal segmental glomerulosclerosis	1.47e-05	7.07e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—CTGF—focal segmental glomerulosclerosis	1.47e-05	7.04e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—SPP1—focal segmental glomerulosclerosis	1.45e-05	6.93e-05	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—GNAQ—focal segmental glomerulosclerosis	1.44e-05	6.88e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—SERPINE1—focal segmental glomerulosclerosis	1.43e-05	6.87e-05	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—LPL—focal segmental glomerulosclerosis	1.43e-05	6.86e-05	CbGpPWpGaD
Ponatinib—FGFR1—Disease—TGFB1—focal segmental glomerulosclerosis	1.42e-05	6.8e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Disease—TGFB1—focal segmental glomerulosclerosis	1.41e-05	6.78e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	1.38e-05	6.63e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—FN1—focal segmental glomerulosclerosis	1.36e-05	6.53e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—GNAQ—focal segmental glomerulosclerosis	1.35e-05	6.48e-05	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	1.35e-05	6.47e-05	CbGpPWpGaD
Ponatinib—ABCG2—Metabolism—ALB—focal segmental glomerulosclerosis	1.31e-05	6.29e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—AGT—focal segmental glomerulosclerosis	1.31e-05	6.26e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	1.29e-05	6.19e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	1.27e-05	6.08e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—LPL—focal segmental glomerulosclerosis	1.24e-05	5.94e-05	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—AGT—focal segmental glomerulosclerosis	1.22e-05	5.87e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—FN1—focal segmental glomerulosclerosis	1.21e-05	5.78e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	1.2e-05	5.77e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	1.2e-05	5.76e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	1.13e-05	5.44e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—LIPC—focal segmental glomerulosclerosis	1.09e-05	5.23e-05	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—LPL—focal segmental glomerulosclerosis	1.08e-05	5.18e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	1.06e-05	5.11e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—AGT—focal segmental glomerulosclerosis	1.06e-05	5.08e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	1.06e-05	5.08e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	1.05e-05	5.01e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—TGFB1—focal segmental glomerulosclerosis	1.02e-05	4.9e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—LPL—focal segmental glomerulosclerosis	1.02e-05	4.88e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	1e-05	4.81e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	9.92e-06	4.76e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	9.9e-06	4.75e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—CTGF—focal segmental glomerulosclerosis	9.6e-06	4.6e-05	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—ALB—focal segmental glomerulosclerosis	9.39e-06	4.5e-05	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—AGT—focal segmental glomerulosclerosis	9.24e-06	4.43e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—TGFB1—focal segmental glomerulosclerosis	9.05e-06	4.34e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—GNAQ—focal segmental glomerulosclerosis	8.84e-06	4.24e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	8.73e-06	4.19e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—AGT—focal segmental glomerulosclerosis	8.7e-06	4.17e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	8.68e-06	4.16e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—ALB—focal segmental glomerulosclerosis	8.14e-06	3.9e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	7.69e-06	3.69e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	7.16e-06	3.43e-05	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—ALB—focal segmental glomerulosclerosis	7.09e-06	3.4e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—ALB—focal segmental glomerulosclerosis	6.68e-06	3.2e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—LPL—focal segmental glomerulosclerosis	6.65e-06	3.19e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	6.34e-06	3.04e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—AGT—focal segmental glomerulosclerosis	5.69e-06	2.73e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—ALB—focal segmental glomerulosclerosis	4.37e-06	2.09e-05	CbGpPWpGaD
